Research On Centralized Drug Purchase Model Based On Patient Brand Preference And Medical Insurance Reimbursement

In order to promote the consistency evaluation of generic drugs,accelerate the replacement of original research drugs by generic drugs,and solve the problems of expensive drugs for patients and inefficient utilization of medical insurance funds,the implementation of centralized procurement of drugs is the development trend of global pharmaceutical procurement.Our country has issued a series of policies to reform the medical procurement model.Among them,the centralized and volume procurement model has achieved initial results,but also has many problems.During the implementation process,it was discovered that patients’ patient brand preference for original research drugs and medical insurance reimbursement policies may have an impact on the implementation effect of the centralized procurement model.Based on the background of my country’s pharmaceutical procurement industry,this article uses a combination of theoretical modeling and numerical simulation to study the decision-making issues of different brand pharmaceutical companies and governments in the competitive market from the perspective of government and enterprises.The main research contents and results are as follows:(1)When the government adopts the strategy of reimbursement of medical insurance drugs in the same proportion,in the market environment of non-centralized procurement model and centralized procurement model,the price optimal decision-making problem of different brands of pharmaceutical companies and the government procurement model selection problem are studied.The results of the study show that the patient brand preference for original research drugs and the economies of scale brought about by centralized and volume procurement will not only intensify competition among enterprises,but also have an impact on the choice of government procurement models.When the patient’s patient brand preference is small or the impact of economies of scale is greater,it is better for the government to adopt a centralized drug procurement model strategy.On the contrary,it is better to choose a non-centralized procurement model.However,the medical insurance drug reimbursement ratio does not have a direct impact on the patient’s choice of drug purchase,but it will lead to patients’ over-reliance on medical insurance reimbursement,which directly affects the expenditure of medical insurance funds and changes in social welfare.(2)When the government adopts the reimbursement method of the same amount of medical insurance drugs,the price decisions of pharmaceutical companies and the government’s procurement mode selection in different market procurement environments are studied.In order to reduce the expenditure pressure of medical insurance funds,the government may encourage patients to purchase generic drugs that have passed the consistency evaluation through the same reimbursement method.The research results show that the same-amount reimbursement method can not only effectively control the market price of the original drug and improve the total social welfare.At the same time,it can also enhance the economies of scale brought about by the centralized procurement with quantity.(3)It compares and analyzes the effects of different reimbursement strategies for medical insurance drugs under different procurement modes from the two aspects of medical insurance fund expenditure and social welfare.The research results show that no matter what kind of procurement mode is adopted,the government’s implementation of the medical insurance drug reimbursement strategy not only saves the expenditure of medical insurance funds,but also has better social welfare.Therefore,when the patient brand preference coefficient is small,the overall social welfare is optimal when the strategy of centralized drug purchase and medical insurance drug reimbursement is implemented.When the patient’s patient brand preference coefficient is large,social welfare is optimal when the non-centralized procurement model and the strategy of reimbursement of medical insurance drugs with the same amount are implemented.